Skip to main content

Table 6 Summary of randomized trials assessing the efficacy of letrozole

From: Hormonal, follicular and endometrial dynamics in letrozole-treated versus natural cycles in patients undergoing controlled ovarian stimulation

Study
(reference number)
Intervention Cohort of patients Conclusion
[20] Letrozole (2.5 mg) Vs CC Infertile women undergoing Superovulation and IUI. Similar endometrial thickness and pregnancy rates.
[21] letrozole Vs CC as adjuvants to rFSH 41 patients Superovulation before IUI in unexplained infertility Better endometrial thickness with letrozole. Similar pregnancy rate
[22] Letrozole Vs CC 74 patients Polycystic ovary syndrome Similar endometrial thickness and pregnancy rate
[23] Letrozole (2.5 mg) Vs CC Polycystic ovary syndrome Better endometrial thickness and pregnancy rate with letrozole.
[24] Letrozole Vs CC Polycystic ovary syndrome No advantage to the use of letrozole over CC as a first-line treatment for induction of ovulation in women with PCOS
[25, 26] Letrozole Vs CC Superovulation before IUI in unexplained infertility No superiority between letrozole and CC for inducing ovulation in women with unexplained infertility before IUI.
[27] Letrozole Vs CC-gonadotropin Superovulation before IUI in unexplained infertility Letrozole is a good alternative to CC-gonadotropin.
[28] Letrozole (2.5 mg) Vs CC 22 patients superovulation in women with normal ovulation CC is superior to 2.5 mg letrozole for superovulation induction in women with normal ovulation.
[29] Letrozole (7.5 mg) Vs CC 46 patients Polycystic ovary syndrome Letrozole has better ovulation and PR in comparison to CC in patients with PCOS